secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-08-21T23:59:59+00:00
Accession:  0001213900-24-071386
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery
--------------------------------------------------------------------------------

- Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.
- Biosynthesis patent for manufacturing proprietary analogs granted in US, issued Sept 3, 2024.
- Ocular drug delivery formulation patent granted/allowed in US, Europe, Australia, Japan, India.
- Total IP portfolio now 13 patent families covering NCEs, formulations, manufacturing, methods of use.
- Company continues pursuing patent protection for INM-901 (Alzheimer's) and INM-089 (dry AMD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/0001213900-24-071386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/ea0212056-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-071386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer